Central Nervous System

Three candidates form the CNS section of the current Vernalis pipeline. Two are in pain therapeutics, including our marketed product, frovatriptan. The third programme is for the potential treatment of Parkinson’s disease.

CNS pipeline

Programmes

Product	Indication	Late Research	Pre-Clinical	Phase I	Phase II	Phase III	Marketed	Marketing Rights	Peak Sales
CNS Programmes
Frovatriptan	Acute Migraine							Menarini / Endo Pharma	$
V158866	Pain							Worldwide	$$$
V81444	Parkinson's Disease							Worldwide	$$

Key

Unpartnered programmes
Partnered programmes
Peak sales: $: < $150m $$: $150-$500m $$$: $500m+

Pain indications

Neuropathic and general pain

As well as potentially addressing general pain indications, certain product candidates focus on neuropathic pain, poorly served by current treatments. It has been estimated that only around 50% of patients experiencing neuropathic pain get any pain relief at all from their treatments, and even when pain relief does occur, it is judged only to be about 50% effective.

Neurological indications

Parkinson’s disease

Diseases of the central nervous system are, unfortunately, many and varied. Many disorders are, as yet, poorly treated, with a lack of effective drugs available. This significant unmet medical need is what prompts Vernalis to pursue possible drug candidates in this area.

Latest News